How the cost-effectiveness results change in the China health policy environment: an economic evaluation of glycopyrrolate/formoterol for the treatment of COPD

Luying Wanga School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China

Weili Gub The First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, Guangzhou, China

Xiao Zhanga School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China

Shihui Fua School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China

Donger Zhanga School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China

Xin Guana School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China

Hongchao Lia School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, ChinaCorrespondence[email protected]

Aixia Maa School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, ChinaCorrespondence[email protected]

show all

How the cost-effectiveness results change in the China health policy environment: an economic evaluation of glycopyrrolate/formoterol for the treatment of COPD

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

How the cost-effectiveness results change in the China health policy environment: an economic evaluation of glycopyrrolate/formoterol for the treatment of COPD

Citations (0)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date